Chang Ansi, Tourtellotte Wallace W, Rudick Richard, Trapp Bruce D
Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
N Engl J Med. 2002 Jan 17;346(3):165-73. doi: 10.1056/NEJMoa010994.
Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination.
Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes.
Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P<0.001).
Premyelinating oligodendrocytes are present in chronic lesions of multiple sclerosis, so remyelination is not limited by an absence of oligodendrocyte progenitors or their failure to generate oligodendrocytes. Our findings suggest that in the chronic lesions of multiple sclerosis, the axons are not receptive for remyelination. Understanding the cellular interactions between premyelinating oligodendrocytes, axons, and the microenvironment of lesions of multiple sclerosis may lead to effective strategies for enhancing remyelination.
多发性硬化是一种中枢神经系统的炎症性疾病,会破坏髓鞘、少突胶质细胞和轴突。由于多发性硬化的大多数病灶无法重新髓鞘化,增强髓鞘再生是一种可能的治疗策略,或许可通过将产生少突胶质细胞的细胞移植到病灶中来实现。我们研究了多发性硬化慢性病灶中少突胶质细胞的频率分布和形态,以确定这些因素是否限制了髓鞘再生。
对10例多发性硬化患者尸检获得的48个慢性病灶进行免疫细胞化学检查,以检测少突胶质细胞和少突胶质前体细胞。使用共聚焦显微镜,我们检查了轴突与少突胶质前体细胞突起之间的三维关系。
48个多发性硬化慢性病灶中的34个含有少突胶质细胞,其具有多个延伸的突起,这些突起与脱髓鞘轴突相关,但未能使其髓鞘化。这些轴突营养不良,含有多个肿胀。在某些区域,少突胶质前体细胞的密度(每平方毫米组织25个)与发育中的啮齿动物脑内的密度(每平方毫米23个)相似。在病程较长(超过20年)的患者中,含有少突胶质前体细胞的病灶较少(P<0.001)。
少突胶质前体细胞存在于多发性硬化的慢性病灶中,因此髓鞘再生不受少突胶质前体细胞缺失或其无法产生少突胶质细胞的限制。我们的研究结果表明,在多发性硬化的慢性病灶中,轴突无法接受髓鞘再生。了解少突胶质前体细胞、轴突和多发性硬化病灶微环境之间的细胞相互作用,可能会带来增强髓鞘再生的有效策略。